Hematologic Malignancies
Arterial stiffness in hematologic malignancies
... linking hematologic malignancies and arterial stiffness, focusing on recent experimental and clinical ...in hematologic malignancies between complete blood count and arterial ...in ...
8
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
... in hematologic malignancies, characterize potential resistance mechanisms to BET inhibitors, and discuss potential combination therapies with BET inhibitors in patients with hematologic ...
11
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
... lymphoid malignancies studied here, the antitumor activity of larotrec- tinib seen here calls for systematic identification of TRK fusions in the clinical evaluation of hematologic malignancy patients with ...
8
Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations
... In a worldwide study of the antimicrobial susceptibil- ities of 1,586 clinical S. maltophilia isolates, SXT and tigecycline showed susceptibilities of 96.0% and 95.5%, respectively, followed by levofloxacin with a ...
8
Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
... inhibitors, ten-eleven translocation 2 (TET2), a dioxy- genase, catalyzes DNA demethylation. TET2 mutations in AML contribute to hypermethylated DNA at en- hancers, resulting in suppression of gene expression. TET2 ...
17
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies
... complexes. Heterozygous loss of CBP impairs HSC self- renewal and predisposes to hematologic malignancies in humans and in mouse models [75]. Consistently, it has been shown that CBP plays an important role ...
24
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
... all hematologic malignancies [18]; those up-regulated in cancer cells generally contribute to carcinogenesis by inhibiting tumor suppressor genes and are considered oncogenic miRNAs (OncomiRs) [19], while ...
25
Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
... Despite recent advances in the treatment of MF, lack of true disease modification following treatment with current therapies warrants the identification of novel therapies. In- hibitors of the Hh signaling pathway, which ...
12
The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation
... various hematologic malignancies and are related with progression or chemotherapy resistance in these ...in hematologic malignancies and in HSCT will be ...of hematologic ...
10
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
... CAR consisting of scFv attached to CD3ζ produces mod- est clinical results as it delivers only the first signal for T cell activation. Second-generation CARs include an add- itional co-stimulatory domain (CD28, 4-1BB, ...
20
Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies
... Improvements in the understanding of the PI3K pathway have led to the rational development and use of PI3K inhibitors, mainly in patients with hematologic malignancies. Idelalisib, a p110-delta inhibitor, ...
10
Expanding role of lenalidomide in hematologic malignancies
... Lenalidomide is an IMiD that has effects on tumor cells and the tumor microenvironment leading to clinical efficacy across a diverse spectrum of hematologic malignancies. Recent insights into the biology of ...
15
The molecular genetics of hematologic malignancies.
... in hematologic malignancies ...cell malignancies, whose lineage was unclear on the basis of morphology and immunopheno- typic studies, have had lineages assigned on the basis of the discovery of ...
8
Vorinostat in solid and hematologic malignancies
... gistic or additive activity in cell lines from a wide range of solid and hematologic malignancies [4,5], including NSCLC [42-46], multiple myeloma (MM) [47-49], and leukemia [45,50-61]). In various models, ...
11
Epidemiology of Candida kefyr in Patients with Hematologic Malignancies
... Candida kefyr is an emerging pathogen among patients with hematologic malignancies (HM). We performed a retrospective study at Johns Hopkins Hospital to evaluate the epidemiology of C. kefyr colonization ...
8
Immunotherapy in hematologic malignancies: past, present, and future
... in hematologic malignancies again with the development of brentuximab, an anti-CD30 antibody linked to a microtubule inhibitor, ...both malignancies in which CD30 is highly expressed, brentuximab ...
10
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
... Results from phase 2 pivotal trials of single-agent brentuximab vedotin (1.8 mg/kg) demonstrated an objective response rate (ORR) of 75% (34% complete remission [CR]) in Hodgkin lymphoma[r] ...
8
Candida guilliermondii Fungemia in Patients with Hematologic Malignancies
... Non-Candida albicans Candida species have been recog- nized as emerging pathogens in cancer patients, particularly those with hematological malignancies. Not only are serious infections caused by these yeast ...
7
Epidemiology and Antifungal Susceptibility Profile of Aspergillus Species: Comparison between Environmental and Clinical Isolates from Patients with Hematologic Malignancies
... Since Denning et al. reported the relationship between azole resistance and poor survival rate in a neutropenic murine model in 1997, azole resistance has been observed to be increasing in clinical A. fumigatus isolates ...
13
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
... Testa and coworkers have explored the possible ef- fects induced by CD123 overexpression at the level of leukemic cells and have shown that: (a) leukemic blasts overexpressing IL-3R α ex[r] ...
11